📊 OGEN Key Takeaways
Is Oragenics Inc. (OGEN) a Good Investment?
Oragenics is in severe financial distress with virtually no revenue ($37.7K), collapsing 71.4% YoY, while burning $9.2M annually in operating cash flow against only $4.4M in remaining cash reserves. The pharmaceutical company exhibits catastrophic operational losses (Operating Margin: -24865%), negative free cash flow, and zero gross profit, indicating fundamental business failure with less than 6 months of cash runway at current burn rates.
Why Buy Oragenics Inc. Stock? OGEN Key Strengths
- Zero financial leverage (Debt/Equity: 0.00x) eliminates debt default risk
- Strong liquidity position (Current Ratio: 5.60x) provides short-term payment flexibility
- Cash reserves of $4.4M provide minimal runway for potential turnaround efforts
OGEN Stock Risks: Oragenics Inc. Investment Risks
- Catastrophic revenue collapse (-71.4% YoY) with only $37.7K quarterly revenue indicates complete loss of market traction
- Operating cash burn of $9.2M annually against remaining cash of $4.4M means <6 months of operational runway at current rates
- Massive operating losses (-$9.4M) with operating margins of -24865% indicate the business cannot sustain operations without continuous cash depletion
- Zero insider Form 4 activity suggests management confidence has evaporated
- Failed pharmaceutical product pipeline with no gross profit indicates commercialization failure
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway countdown
- Any revenue stabilization or growth inflection signs
- Product pipeline updates, clinical trial results, or partnership announcements indicating potential turnaround
- Operating expense restructuring or cost reduction actions
- Capital raise announcements or dilutive financing activities
Oragenics Inc. (OGEN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.60x current ratio provides a solid financial cushion.
OGEN Profit Margin, ROE & Profitability Analysis
OGEN vs Healthcare Sector: How Oragenics Inc. Compares
How Oragenics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Oragenics Inc. Stock Overvalued? OGEN Valuation Analysis 2026
Based on fundamental analysis, Oragenics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Oragenics Inc. Balance Sheet: OGEN Debt, Cash & Liquidity
OGEN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Oragenics Inc.'s revenue has declined by 57% over the 5-year period, indicating business contraction. The most recent EPS of $-47.88 indicates the company is currently unprofitable.
OGEN Revenue Growth, EPS Growth & YoY Performance
OGEN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $7.5K | -$2.0M | $-0.38 |
| Q2 2024 | $13.2K | -$2.3M | $-0.51 |
| Q1 2024 | $17.0K | -$2.5M | $-0.70 |
| Q3 2023 | $7.5K | -$2.0M | $-0.85 |
| Q2 2023 | $13.2K | -$2.8M | $-1.51 |
| Q1 2023 | $15.1K | -$2.8M | N/A |
| Q3 2022 | $86.0K | -$3.8M | N/A |
| Q2 2022 | $30.4K | -$3.8M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Oragenics Inc. Dividends, Buybacks & Capital Allocation
OGEN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Oragenics Inc. (CIK: 0001174940)
📋 Recent SEC Filings
❓ Frequently Asked Questions about OGEN
What is the AI rating for OGEN?
Oragenics Inc. (OGEN) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are OGEN's key strengths?
Claude: Zero financial leverage (Debt/Equity: 0.00x) eliminates debt default risk. Strong liquidity position (Current Ratio: 5.60x) provides short-term payment flexibility.
What are the risks of investing in OGEN?
Claude: Catastrophic revenue collapse (-71.4% YoY) with only $37.7K quarterly revenue indicates complete loss of market traction. Operating cash burn of $9.2M annually against remaining cash of $4.4M means <6 months of operational runway at current rates.
What is OGEN's revenue and growth?
Oragenics Inc. reported revenue of $37.7K.
Does OGEN pay dividends?
Oragenics Inc. does not currently pay dividends.
Where can I find OGEN SEC filings?
Official SEC filings for Oragenics Inc. (CIK: 0001174940) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is OGEN's EPS?
Oragenics Inc. has a diluted EPS of $-4.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is OGEN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Oragenics Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is OGEN stock overvalued or undervalued?
Valuation metrics for OGEN: ROE of -118.9% (sector avg: 15%), net margin of -26,140.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy OGEN stock in 2026?
Our dual AI analysis gives Oragenics Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is OGEN's free cash flow?
Oragenics Inc.'s operating cash flow is $-9.2M, with capital expenditures of $127.5K. FCF margin is -24,895.5%.
How does OGEN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -26,140.0% (avg: 12%), ROE -118.9% (avg: 15%), current ratio 5.60 (avg: 2).